Clinilabs Strengthens Leadership Team to Enhance CNS Drug Development Services

Clinilabs, LLC, a prominent contract research organization (CRO) specializing in central nervous system (CNS) drug and medical technology development, has recently expanded its executive leadership team with the appointments of David Hagerman as Chief Financial Officer (CFO) and Jeanine Falinski as Senior Vice President of Commercial Development. This development is significant as it highlights Clinilabs' commitment to enhancing its leadership and commercial strategies to support its growth trajectory in the highly competitive CNS sector.

David Hagerman brings over 25 years of financial leadership experience in the life sciences and IT industries to his new role as CFO at Clinilabs. His extensive background, including previous positions at X-Chem, Charles River Laboratories, and Parexel, is expected to play a pivotal role in steering the company's financial operations and strategic planning. Jeanine Falinski, with her 20 years of pharmaceutical industry experience and a history of progressive leadership roles within Clinilabs, is set to lead the commercial team, further strengthening the company's market position and customer engagement strategies.

The appointments come at a time when the demand for innovative CNS therapies is on the rise, with an increasing number of pharmaceutical and biotechnology companies seeking specialized CROs to navigate the complexities of CNS drug development. Clinilabs' focus on CNS disorders, including psychiatric, neurological, and substance use disorders, positions it as a key player in addressing some of the most challenging health issues facing the global population today.

The strategic enhancement of Clinilabs' leadership team underscores the company's dedication to delivering high-quality, timely, and cost-effective development services for CNS drugs, devices, and technologies. With a track record of contributing to the approval of 23 new therapies across 14 CNS indications, Clinilabs' continued investment in leadership and commercial capabilities is a positive signal to the industry and patients awaiting new treatments.